To compare the effects of a standard American diet, a traditional low-fat diet, and a low-fat diet containing the fat substitute olestra on risk factors for heart disease and diabetes. DESIGN: A 9-month, double-blind, randomized, parallel-arm, feeding study comparing three diets: (1) control (33% fat), (2) fat-reduced (FR; 25% fat), and (3) fat-substituted (FS) where olestra replaced 1/3 of dietary fat (33% lipid and 25% digestible fat). Subjects were allowed to adjust their total energy intake as desired, allowing weight to fluctuate. SUBJECTS: A total of 37 healthy, obese men (age 36.771.3 y; body mass index 30.870.4 kg/m 2 ). MEASUREMENTS: Body weight and composition by dual-energy X-ray absorptiometry, blood pressure, serum lipids, lipoproteins, hemostatic factors, glucose, insulin, and leptin at baseline and every 3 months. RESULTS: The FS group lost 6.27 kg of body weight by 9 months vs 4.0 kg in the control and 1.79 kg in the FR groups. There was a significant diet main effect on cholesterol (P ¼ 0.002), low-density lipoprotein cholesterol (P ¼ 0.003), and triglycerides (P ¼ 0.01), all of which decreased in the FS group but not the other groups by 9 months. Apolipoprotein B (ApoB) increased in the FR and control groups but was unchanged in the FS group (diet main effect P ¼ 0.04). High-density lipoprotein (HDL) cholesterol increased in all groups over 9 months (time main effect P ¼ 0.0001). Time main effects were also observed for cholesterol, ApoA1, ApoB, Factor VII, diastolic blood pressure, and glucose. After adjustment for % fat loss at 9 months, the effects of diet on change in risk factors remained significant only for triglycerides. DISCUSSION: Consumption of a low-fat diet containing olestra for 9 months produced significant improvement in cardiovascular risk factors, an effect largely explained by weight loss. Long-term low-fat diet consumption with or without olestra does not decrease HDL cholesterol.
Introduction
The role of low-fat diets in improving health risk factors for cardiovascular disease and type II diabetes is somewhat controversial. While isocaloric low-fat diets have been shown experimentally to lower total and low-density lipoprotein (LDL) cholesterol relative to high-fat diets, they also appear, at least in the short term, to lower high-density lipoprotein (HDL) cholesterol [1] [2] [3] and raise serum triglycerides. 1 This has caused some to argue that low-fat diets may not be the best nutritional approach for preventing heart disease, 4 although the effect of low-fat diets on lipids is clearly impacted by whether weight is maintained or decreasing. 5 With regard to risk factors for diabetes, it has been shown in a number of studies that isocaloric low-fat diets improve insulin sensitivity whereas high-fat diets worsen it. [6] [7] [8] Weight loss, on the other hand, seems to clearly improve both cardiovascular and diabetes risk factors. For example, 2-y follow-up data from the Swedish Obesity Study showed a linear decrease in serum glucose, insulin, and triglyceride concentrations with increasing weight loss. 9 Serum HDL cholesterol concentrations rose in parallel with weight loss. Serum LDL and total cholesterol concentrations did not decrease with weight loss until body weight had decreased by 20%. Furthermore, it is well known that type II diabetes mellitus is associated with obesity, and that even modest weight loss can result in substantial improvements in glycemic control. 10 Weight loss may also prevent the progression of impaired glucose tolerance to overt diabetes. 11 The availability of olestra, a fat substitute that has the mouth feel of dietary fats but that cannot be digested in the intestine, provides a method for the covert replacement of dietary fat in the diet. No studies, to our knowledge, have examined the long-term effects of low-fat diets on health risk factors using a controlled feeding paradigm where body weight is allowed to fluctuate naturally. The 9-month feeding trial reported here was designed primarily to test the hypothesis that covert substitution of olestra for dietary fat would significantly reduce body weight and body fat. The weight loss results have been reported elsewhere. 12 In the present report, we tested the hypothesis that low-fat diets and/or weight loss on a long-term feeding study would improve risk factors for cardiovascular disease and diabetes.
Methods

Subjects
A total of 164 subjects were screened for this protocol and 45 eligible men were enrolled. Subjects were told that the purpose of the study was to assess the effect of diet on health risk factors and there was no mention of weight loss. To be eligible for the trial, the subjects had to be healthy, age 21-60 y, with a body mass index (BMI) between 27 and 35 kg/m 2 . Smokers, trained athletes, men on special diets, individuals with chronic illnesses or gastrointestinal disease, men with more than three bowel movements per day, subjects whose weight had varied by more than 3 kg in the past 6 months, and men with food preferences that would not fit into the planned menus were excluded from consideration. Subjects gave informed consent prior to participation and the advertisements, the protocol, and the consent form were approved by the Pennington Biomedical Research Center's Institutional Review Board.
Experimental design
The design of the trial has been described elsewhere. 12 The study was a double-blind, parallel-arm, randomized, controlled feeding trial comparing three diets. Following a 3-week run-in period during which all subjects ate the 33% fat control diet, subjects were randomized to one of the three diet arms (N ¼ 15 per arm) based on a randomization scheme that stratified for age, initial BMI, and screening cholesterol level. The control diet was 33% fat, 52% carbohydrate, and 15% protein. There were two low-fat arms: one in which 1/3 of the fat was replaced with olestra (fat-substituted (FS) diet) to produce a diet with 25% available fat calories, 58% carbohydrate, and 17% protein; and the other which was a standard fat-reduced (FR) diet with macronutrient composition identical to the FS diet. Nutrient composition of the diets is shown in Table 1 . Olestra was incorporated into a variety of baked goods, salted snacks, and entrées, and the general type and variety of foods were the same for all groups. Foods that contained olestra were indistinguishable from non-olestra containing foods during taste tests. Diets were prepared at levels of 7524, 9196, 10 868, 12 540, 14 212, and 15 466 kJ (1800, 2200, 2600, 3000, 3400, and 3700 kcal/ day) and the menus were taste-tested for acceptability by the subjects. For energy levels between these values, participants received one, two, or three mandatory ''energy booster'' unit-foods of 418 kJ (100 kcal) each, including a chocolate cheesecake, chocolate muffin, or Mexican cornbread. Although subjects were not given any indication that weight loss was a goal of the study, the study was designed to allow weight to fluctuate somewhat naturalistically. Thus, the caloric level of the FS and FR diets was designed to be 11% less than energy needs determined during the run-in phase (Table 1 ). This was accomplished by reducing the number of unit foods and/or the basal diet caloric level. However, subjects in any of the groups who felt hungry could request 'snack packs' that contained 100 kcal in the standard diet group and 89 kcal in the other two groups in addition to the provided meals. Similarly, if any subject felt he was being given too much food, he could reduce the number of snack packs consumed. Snack packs did not contain olestra and consisted of Graham crackers and yogurt, cheese and crackers, bean dip and tortillas, or bagel chips with cream cheese. Data on the number of snack packs requested by subjects in the different groups have been reported by Bray et al.
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Monday through Friday, with other meals packed for takeout. Adherence to the study diets was assessed by daily interviews. Food intake and the number of snack packs requested by each subject were recorded daily. These results have been reported elsewhere. 12 The men were allowed to consume one alcoholic beverage per day and up to five caffeine-containing beverages per day including coffee, tea, or sugar-free cola. They were given three holiday weekend breaks (Easter, July 4, and Labor Day) and were permitted seven additional sick or vacation days to use at their discretion over the 9 months. A 5-day meal rotation was used and a total of 10 different menu plans were used throughout the study.
Outcome measures
Body weight and composition (fat and lean tissue) were determined by dual-energy X-ray absorptiometry (DEXA) at the end of the run-in period (baseline), and at 3, 6, and 9 months. Body weight was also measured weekly by kitchen staff using an electronic scale to monitor more frequent fluctuations in weight. Blood pressure was measured in duplicate on each of three separate days using a random-zero blood pressure manometer by nurses certified for blood pressure measurement. Data collection staff were masked to treatment assignment.
Blood samples were drawn at baseline and at 3, 6, and 9 months for measurement of total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, fibrinogen, Factor VII, apolipoproteins A1 (ApoA1) and B (ApoB) , glucose, insulin, leptin, and C-reactive protein. Blood was collected after an overnight fast using a 20-gauge butterfly set to minimize hemolysis. Collection tubes containing 3.2% sodium citrate were used for fibrinogen and Factor VII analyses. Samples were stored at room temperature (glucose, lipids, apolipoproteins, insulin, and Factor VII) or on ice (fibrinogen) immediately after collection. Blood was centrifuged at 3000 Â g for 15 min. Fibrinogen tubes were centrifuged at 41C and all other samples were spun at room temperature. Serum or plasma was aliquoted into plastic cryovials and frozen at À801C until analyzed. All analyses were performed in batch at the end of the study to minimize interassay variations on the outcome variables.
Glucose, cholesterol, HDL cholesterol, and triglycerides were analyzed on a Beckman Coulter Synchron CX7 (Brea, CA,USA). LDL cholesterol was derived using the Friedewald calculation. Insulin was measured using a microparticle enzyme immunoassay on the Abbott IMX (Abbott Park, IL, USA). ApoA1 and ApoB were measured using nephelometry on a Beckman Coulter Array (Brea, CA, USA), Factor VII and fibrinogen were measured using an IL ACL 3000+(Lexington, MA, USA), and C-reactive protein was measured on a DPC Immulite analyzer (Los Angeles, CA, USA). Leptin was measured by radioimmunoassay (Linco; St Louis, MO, USA). The Clinical Chemistry Laboratory at the Pennington Center participates in the CDC Lipid Standardization program and is certified by the American College of Pathologists.
Data analysis
Data were analyzed using a repeated measures design with time in 3-month units as a repeated factor, treatment and time as fixed main effects together with the time-bytreatment interaction in the model. For testing of all hypothesis, the Type III tests were used. This procedure creates a Type III estimable function for each tested effect that zeros out the remaining effects and then a corresponding F-test is constructed with appropriate numerator and denominator degrees of freedom. All group comparisons were adjusted for baseline value as a covariate. To estimate sample size, a power analysis was performed using the variance in weight loss from two previous short-term trials with olestra. 13 A sample of 12 subjects in each cell at the end of the study was estimated to detect a difference in change from baseline to 9 months of at least a 4 kg between the treatment groups with an alpha of 0.05 and at least 80% power. Since BMI, age, and total cholesterol are associated with weight loss, participants were stratified with respect to these variables in order to achieve balance at baseline between the three treatment groups. Owing to their nonnormal distribution, insulin and triglycerides were transformed logarithmically for analysis. Additional analysis of covariance was used separately to control for change in body fat or weight in assessing the impact of diet on health risk factors. A Tukey-Kramer multiple comparison adjustment was used and an adjusted P-value of less than 0.05 was considered significant. For the analysis, statistical procedures Proc Mixed and Proc GLM in SAS Version 6.12 and Version 8.1 (SAS, Inc., Cary, NC, USA) were used.
Results
Of the 45 men enrolled, 37 completed the entire 9 months of the study. The mean age of the group at baseline was 36.771.3 (s.d.) y and the BMI was 30.870.4 kg/m 2 . Since subjects were stratified by age, baseline BMI, and serum total cholesterol at randomization, there was no significant difference at baseline among the three diet groups for these variables. 12 As previously reported, 12 subjects in the FS group lost 6.2771.66 kg of body weight (Po0.0001) by 9 months while men in the control group lost 4.071.25 kg of body weight (Po0.0001), and those in the FR group lost 1.7970.81 kg of body weight (NS). The majority of subjects in all groups were weight stable (72 kg) from 6 to 9 months (Table 2) ; thus, the final study measurement was made under conditions of relative weight stability. The changes from baseline in serum lipids and lipoproteins are shown in Table 2 . There were significant diet main effects on change in cholesterol and LDL cholesterol from baseline. Total cholesterol was reduced in the FS group compared to the FR diet groups at 9 months (P ¼ 0.02), but there was no difference between the FS and control groups at Low-fat diet wtih olestra produces weight loss and lowers health risks JC Lovejoy et al this time point. The changes in LDL cholesterol were similar to those of total cholesterol at 9 months (P ¼ 0.09 FS vs FR and P ¼ 0.16 FS vs control). There was also a diet main effect on triglycerides, which were increased on the control and FR diets but decreased on the FS diet by 9 months. The difference between triglycerides on the FS and FR diets at 9 months was statistically significant (P ¼ 0.02), although that between FS and control diets was not. ApoB levels were higher by 9 months in the control and FR groups but was unchanged in the FS group (diet main effect P ¼ 0.04). Main effects of time were observed for total cholesterol, HDL cholesterol, ApoA1, ApoB, Factor VII, diastolic blood pressure, and glucose; however, there were no significant differences among diets on any of these variables ( Table 2 ). Since changes in serum lipids are influenced by the fatty acid composition of the diet, we calculated the predicted change in total cholesterol, LDL and HDL cholesterol using the prediction equations of Mensink and Katan. 1 For control vs FS diets, the predicted changes in all lipids were substantially smaller than the observed changes. For example, predicted change in total cholesterol based on the fatty acid changes between FS and control diets was À0.9 mg/dl, while the observed change was À10.4 mg/dl. For the control vs FR diet, the prediction equation estimated an increase of 0.4 mg/dl in total cholesterol and a decrease of 0.2 mg/dl in LDL cholesterol, while the observed changes in these lipids were +14.0 and +3.6 mg/dL, respectively. Thus, changes in dietary fatty acids are not likely to be primarily responsible for mediating the observed changes in serum lipids. Table 2 shows changes in fasting glucose and insulin over time in the three diet groups. Glucose showed a significant time main effect (P ¼ 0.006), with no significant effect of diet. By the end of 9 months, fasting glucose was slightly reduced in the control and FS groups, respectively, and had increased in the FR group (not statistically significant). There were also no significant effects of diet on fasting insulin, although by 9 months insulin concentrations were decreased by 5.573.7 mU/ml (32.8721.9 pmol/l) in the FS group whereas they increased in the other two groups.
As previously reported, subjects in the FS group lost significantly more weight than subjects in the other two groups. 12 Leptin concentrations tended to track changes in body composition, as expected ( Table 2 ). The main effect of diet was of borderline statistical significance (P ¼ 0.08) and fasting leptin had decreased significantly in the FS group at both 6 and 9 months compared to baseline (Po0.01). Changes in fasting leptin in the control and the FR groups were not statistically different from baseline at 9 months. Since most of the health risk factors we measured are influenced by body weight, an analysis of covariance was performed to control for the impact of changes in body weight and body fat on cardiovascular and diabetes risk factors. The results of this analysis are shown in Table 3 . After controlling for the change in body fat, there was no significant effect of diet on any health risk factor, with the exception of triglycerides (P ¼ 0.05), suggesting that the beneficial changes observed on the FS diet were primarily due to greater weight loss. Additionally, we compared changes in risk factors in subjects who lost weight vs those who did not lose weight within groups. Although the numbers who did not lose any weight were small (2-4 per group), this comparison generally indicated improvements in risk factors in those who lost weight with no change or deterioration in risk factors in those who did not (data not shown).
Discussion
The replacement of dietary fat with olestra resulted in a number of important changes in health risk factors relative to a standard low-fat diet or typical American diet over 9 months. Our results show that men eating the FS diet had significant reductions in cholesterol, LDL cholesterol, triglycerides, and relatively smaller increases in ApoB concentrations compared to the other two diet groups. We previously reported that consuming a low-fat olestra-substituted diet resulted in significantly greater losses of body weight and Table 3 Independent effects of body fat change (9 months -baseline) and diet on change from baseline in response variables at 9 months.
% Body fat change
Diet main effect adjusted for % body fat change Low-fat diet wtih olestra produces weight loss and lowers health risks JC Lovejoy et al body fat over 9 months compared to standard low-fat or control diets, likely due in part to olestra's effects on gastric distension and other gastrointestinal signals that regulate feeding. 12 In the present study, it appeared that most of the benefits of the FS diet on health risk factors were due to the greater weight loss. Reduction in dietary fat is associated with modest decreases in body weight. [14] [15] [16] Low-fat diets with reduced saturated fat and cholesterol levels have also been shown to reduce LDL cholesterol levels. [1] [2] [3] 17 The present study demonstrated that a weight-reducing, 25% fat, olestracontaining diet fed for 9 months significantly reduced total and LDL cholesterol compared to a control 33% fat diet or standard 25% fat diet. Although dietary saturated fat was somewhat reduced on the FS diet compared to the control (Table 1) , the predicted changes in serum lipids from changes in fatty acid composition based on standard equations were considerably less than the observed changes. Furthermore, levels of saturated fat on the FR diet were even lower than on the FS diet, yet serum lipids were not significantly reduced on this diet. These findings suggest that the decrease in total cholesterol and LDL cholesterol on the FS diet was due to mechanisms other than changes in dietary fatty acids. One likely mechanism to explain the lipid changes in the FS group is the fact that replacing dietary fat with olestra reduces the absorption of dietary cholesterol, 18 hence lowering plasma LDL cholesterol concentration. 19 Additionally, the loss of body weight per se may have contributed to a further reduction in plasma lipids. Importantly, after 9 months on a 25% fat diet, either with olestra or traditional low-fat foods, there was no significant reduction in HDL cholesterol. This result contrasts with previous studies of weight-maintaining low-fat diets, which suggest that reducing dietary fat decreases HDL cholesterol relative to high-fat diets. 3, 17, 20 It is particularly intriguing that the FR group showed a slight increase in HDL cholesterol at 9 months, despite the fact that they did not lose weight by the end of the trial. Since all three groups had decreases in HDL cholesterol at the 3-month time point, it suggests that any effect of low-fat diets to lower HDL cholesterol is transient. Thus, findings of previous shortterm studies of low-fat diets may not be relevant to longterm effects of low-fat diet consumption. Low-fat diets have also been found in previous studies to raise serum triglycerides to a greater extent than high-fat diets. 1, 20 Unlike the improvements in HDL cholesterol seen in both low-fat diet groups, subjects in the FR group who did not lose weight showed the expected elevation in serum triglycerides, while men in the FS group had a decrease in triglycerides (Table 2 ). This observation suggests that it may be the weight-maintaining aspect of previous clinical trials of low-fat diets that resulted in increases in serum triglycerides. Consistent with this idea, the Dietary Approaches to Stop Hypertension (DASH) study found that the low-fat DASH diet did not significantly raise triglycerides, even in a weightmaintaining population. 3 One reason may be that the increase in serum triglycerides on low-fat diets occurs only when the carbohydrate source is high in sucrose and low in fiber, 21, 22 which was not the case in the DASH study. In the present study, dietary fiber was comparable across all three study groups (Table 1) , so differences in type of carbohydrate are unlikely to explain the differences in triglyceride response. Part of the effects of fiber and carbohydrate type in the context of low-fat diets may be their impact on insulin release, which would be greater in high-sucrose, low-fiber diets. In the present study, insulin levels were slightly (although not significantly) higher in the FR group at 9 months. This may be indicative that this group was consuming more total carbohydrate at this time, which is consistent with the speculation that these subjects were unable to adhere to the prescribed diet and thus gained weight. Regardless of the mechanism, however, it appears that when individuals adhere to a long-term low-fat diet and lose weight, beneficial effects on both triglycerides and HDL cholesterol are observed.
Although not statistically significant, the substitution of dietary fat with olestra produced a substantial reduction in insulin by 9 months, in contrast to the increase in fasting insulin seen in the control and FR groups at 9 months. To the extent that fasting insulin reflects whole-body insulin sensitivity, this result is consistent with previous reports showing improvements in insulin sensitivity with both weight loss 23 and isocaloric low-fat diets. 7 These normoglycemic men showed no diet effects on glucose, although glucose concentrations declined significantly across the study in the group as a whole. A decline in glucose associated with decreases in body weight is consistent with the results of Lovejoy and DiGirolamo, 24 which showed a direct, linear correlation between fasting glucose and degree of overweight. Certain hemostatic factors, particularly Factor VII, have previously been reported to be beneficially affected by lowfat diets. 25 In the present study, neither Factor VII nor fibrinogen differed significantly among diet groups over the course of the study and no adverse effects of either low-fat diet were observed. C-reactive protein was also not affected by diet. Leptin, a peptide synthesized and secreted from adipocytes, is thought to be a regulatory signal for control of body fat, since human beings who lack leptin are markedly overweight 26 and treatment with leptin reduces food intake and body weight. 27 In the present study, leptin levels by 9 months had decreased most in the FS group, which lost the most body weight and body fat. Serum leptin was slightly decreased in the control group by 9 months and was slightly increased in the FR group, which had returned to baseline weight by this time.
Analysis of covariance suggested that body fat change is the primary predictor of change in most of the health risk factors measured (Table 3) , while diet per se, after adjusting for the change in body fat, only predicted the triglyceride Low-fat diet wtih olestra produces weight loss and lowers health risks JC Lovejoy et al change. Comparison of subjects who lost weight vs those who did not tended to support this conclusion, although the numbers were small and the differences not statistically significant. Thus, low-fat diets when accompanied by weight loss appear to have health benefits for obese men. It is likely that similar results would be obtained in obese women or nonobese populations; however, to our knowledge this has not been tested in a long-term feeding trial.
In conclusion, the present study demonstrated that when low-fat diets with weight loss are consumed long-term, improvement in cardiovascular and metabolic risk factors occurs. Fat substitutes may improve the ability of individuals to adhere to low-fat diets long-term, since in the present study subjects in the standard low-fat diet condition were unable to maintain weight loss over 9 months, perhaps due to difficulties adhering to the diet. In contrast to previous reports, no adverse effects of either low-fat diet on HDL cholesterol were seen in the present long-term study, and increases in triglycerides with a low-fat diet were only observed when body weight was not reduced (ie in the FR group). These results suggest that promotion of the health benefits of low-fat/reduced-calorie diets accompanied by weight loss, and determination of methods to improve adherence to such diets, may result in substantial public health benefits by reducing obesity and risk for cardiovascular disease and diabetes.
